Lineage Cell Therapeutics FY2029 EPS Reduced by B. Riley

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Analysts at B. Riley dropped their FY2029 earnings per share estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Friday, May 23rd. B. Riley analyst M. Mamtani now anticipates that the company will earn $0.16 per share for the year, down from their prior estimate of $0.20. B. Riley currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.12) per share.

LCTX has been the topic of several other research reports. D. Boral Capital reiterated a “buy” rating and set a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday, March 11th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $4.20.

Lineage Cell Therapeutics Price Performance

Shares of LCTX stock opened at $0.68 on Monday. Lineage Cell Therapeutics has a 1-year low of $0.37 and a 1-year high of $1.15. The stock has a market capitalization of $150.52 million, a PE ratio of -5.69 and a beta of 1.21. The business has a 50-day moving average of $0.47 and a 200 day moving average of $0.62.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of LCTX. Fort Sheridan Advisors LLC lifted its stake in shares of Lineage Cell Therapeutics by 71.5% during the fourth quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock worth $28,000 after buying an additional 23,000 shares during the period. Atria Wealth Solutions Inc. purchased a new position in shares of Lineage Cell Therapeutics in the fourth quarter worth about $29,000. HighTower Advisors LLC increased its holdings in Lineage Cell Therapeutics by 49.5% in the 4th quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock worth $29,000 after buying an additional 19,100 shares during the period. SG Americas Securities LLC lifted its stake in Lineage Cell Therapeutics by 35.5% during the 4th quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after acquiring an additional 18,053 shares during the period. Finally, Two Sigma Advisers LP increased its stake in shares of Lineage Cell Therapeutics by 312.2% in the fourth quarter. Two Sigma Advisers LP now owns 86,964 shares of the company’s stock worth $44,000 after acquiring an additional 65,864 shares during the period. Institutional investors own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.